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LETTERS TO THE EDITORRegarding “A randomized double-blind trial of
upward progressive versus degressive compressive
stockings in patients with moderate to severe chronic
venous insufﬁciency”
I read with great interest the article by Couzan et al entitled
“A randomized double-blind trial of upward progressive vs degres-
sive compressive stockings in patients with moderate to severe
chronic venous insufﬁciency” and congratulate the authors on
their very interesting study.1
Their randomized double-blind trial revealed that progressive
compressive stockings are more effective than usual degressive
compressive stockings in improving pain and lower leg symptoms
in patients with chronic venous insufﬁciency.
Compressive stockings are considered an excellent adjuvant
therapy for treatment of pain and other symptoms in patients with
various leg disorders. Compression therapy is well known for
improving venous outﬂow and reducing edema by increasing the
interstitial pressure of soft tissues. Recently, we developed a novel
leg supporter with an innovative design (Fig). According to our
preliminary study with various ambulatory patients, our leg
supporter revealed a signiﬁcantly decreased degree of leg edema
and fatigue ratio and improved body stability compared with
conventional degressive compressive stockings. In terms of pressure
distribution, our leg supporter was differentiated frompreviously re-
ported graded degressive compressive stockings. Ankle pressure was
23.2 mm Hg, lower calf pressure 38.1 mm Hg, upper calf pressureFig. External appearance of the novel leg supporter.31.0 mm Hg, and knee pressure 11.8 mm Hg. As Couzan et al
implicated in their study, high ankle pressures in graded degressive
compressive stockings lead to low compliance in many elderly
patients. In addition, our leg supporter can be applied to athletes
and to standing workers. Our leg supporter has substantial versa-
tility, so it is possible to apply it to upper extremities.
Again, I thank Couzan et al for their insightful research and
hope that they will apply our novel leg supporter to their clinical
practice successfully.
I thank the study participants and physical therapists and other
staffs of Jaseng Hospital of Oriental Medicine, Seoul, Republic of
Korea (Song Hyuk and Lim Dong-Chun), and I also thank
Dr Whang Kwi-Whan (Miz Aesthetic Clinic, Seoul, Republic of
Korea) for his support for the study.
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Regarding “Symptomatic venous thromboembolism
after femoral vein harvest”
We read with great interest the article by Dhanisetty et al,1
which reports a high 29% incidence of venous thromboembolism
(VTE) after femoral vein harvest (FVH), with the vast majority
of cases (16/17) being ipsilateral deep vein thrombosis distal to
the FVH site. Interestingly, in their discussion, Dhanisetty et al
suggested that therapeutic anticoagulation is not indicated imme-
diately postoperatively in patients who undergo FVH; rather, they
advocated prolonged prophylaxis with low-molecular-weight
heparin (LMWH). However, in the same article, no cases of
VTE in patients who were receiving therapeutic anticoagulation
(16%) after surgery were reported. Postoperative thrombosis was
also observed in 22% of limbs in the retained venous stump within
1 week of operation in a series reported by Wells et al,2 in which no
anticoagulants were given.
We would like to add our own experience with nine FVH
cases. All were followed up prospectively with duplex scanning,
all but one received therapeutic anticoagulation with LMWH for
10 to 30 days postoperatively, and all wore elastic stockings for
at least 3 months. We have never harvested vein length up to
the knee, always sparing the popliteal vein. Using a similar
approach, Modrall et al3 reported the absence of acute or chronic
venous morbidity if the popliteal vein was not harvested.
In most of our patients, the indication for FVHwas transposed
femoral vein arteriovenous access creation after exhaustion of access
sites in the upper limbs (Table).4 Only one popliteal stump throm-
bosis was detected in the patient who did not receive therapeutic
anticoagulation. No bleeding complications were noted.
Based on these data, we do not believe that prolonged
prophylaxis with LMWH is the best method for avoiding post-
FVH VTE as suggested by Dhanisetty et al. It remains our practice299
Table. Femoral vein harvest cases: Indications and duplex follow-up
No. Age/gender Indication for femoral vein harvest Follow-up Duration of therapeutic anticoagulation Duplex/CEAP
1 79/M Femoral vs AV access 13 months 10 days No DVT/C0
2 78/M Femoral vs AV access 12 months 10 days No DVT/C0
3 67/M Portal vs repair 1 montha 30 days —
4 62/M Iliac graft infection 19 months 10 days Amputation
5 45/M Femoral vs AV access 21 months 10 days No DVT/C5
b
6 73/F Femoral vs AV access 18 months 30 days No DVT/C0
7 86/F Femoral vs AV access 3 daysc 3 days —
8 74/M Femoral vs AV access 7 months 30 days No DVT/C0
9 61/M Mycotic AAA repair 5 months Thromboprophylaxis only Stump DVT/C3
AAA, Abdominal aortic aneurysm; AV, arteriovenous; CEAP, clinical, etiology, anatomy, pathophysiology classiﬁcation; DVT, deep vein thrombosis;
F, female; M, male.
aDeath postoperative day 30.
bHealed ulcer from previous to femoral vein harvest suppurative superﬁcial thrombophlebitis.
cDeath postoperative day 3.
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for at least 10 days postoperatively.
Despite the fact that thrombosis in the retained venous stump
is of questionable clinical consequence, there is always concern of
a lag time of several years before the full extent of any venous
morbidity would be noted clinically. The possibility of thrombosis
distal to the vein harvest and any subsequent venous morbidity
should be minimized by proper therapeutic anticoagulation in
the immediate postoperative period, allowing time for optimal
venous collateral circulation remodeling.
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Reply
We greatly appreciate the opportunity to reply to this well-
formulated Letter to the Editor. Deep vein thrombosis (DVT) is
a frequent clinical sequela of the femoral vein harvest (FVH)
procedure. In our study, we observed a high rate of DVT after
FVH only in patients with cancer. Also, DVTs proximal to the
FVH segment were observed only in patients with cancer. Thus,
our recommendation for prophylactic low-molecular-weight
heparin in the postoperative period was for these patients with
cancer to prevent DVT proximal to the harvested femoral vein.The majority of DVTs occurring after FVH were diagnosed
in the retained popliteal vein stump, as correctly pointed out by
the authors in the Letter to the Editor. In our study, the incidence
of retained venous stump DVT was signiﬁcantly lower in patients
without cancer (10% vs 52%). We agree that limited information is
available about the clinical consequence of DVT in the popliteal
vein stump. The study by Wells et al,1 in which 16 limbs with
thrombus in the retained popliteal vein segment after FVH were
compared with 70 limbs without DVT, provides some insight.
Over a mean follow-up period of 3 years, they did not observe
any additional morbidity in limbs with popliteal DVT compared
with limbs without DVT. In that study, none of the patients
were treated for DVT in retained popliteal segment.1 Given
these limited data, we do not routinely treat DVT distal to the
FVH site.
It is always ideal to prevent a DVT, even one with questionable
clinical consequence. However, the optimal method for preventing
a popliteal DVT after FVH is uncertain. Therapeutic anticoagula-
tion is one option. However, in patients without cancer, most of
whom do not develop DVT in the distal vein segment, giving ther-
apeutic anticoagulation in the immediate postoperative period
would expose most of them to the risks of anticoagulation with
minimal beneﬁt. Moreover, the duration of therapeutic anticoagu-
lation to prevent popliteal DVT after FVH is somewhat arbitrary.
Based on our data, a signiﬁcant number of DVTs were diagnosed
more than 10 days after the procedure. Thus, administering thera-
peutic anticoagulation for the ﬁrst 10 days (as suggested by the
authors) may not prevent a signiﬁcant proportion of DVTs in the
retained popliteal vein stump. Given the low incidence of popliteal
DVT in patients without cancer, it is difﬁcult to justify therapeutic
anticoagulation in this population, especially when the clinical
consequence of DVT in the distal popliteal vein is minimal. It is
an interesting proposition to investigate the role of therapeutic anti-
coagulation in cancer patients who require an FVH procedure to
prevent DVT proximal to the harvest site.
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